Dr S. Shahzad Mustafa describes how the upcoming 2025 American College of Allergy, Asthma and Immunology Annual Scientific Meeting will feature an exciting and comprehensive agenda, particularly highlighting advances in chronic spontaneous urticaria therapies. With three FDA-approved treatments for chronic urticaria now available — omalizumab, dupilumab, and remibrutinib — the field is progressing rapidly, offering new options for patients.
The meeting will also address the emerging importance of disease phenotyping to help clinicians personalize therapy choices as options expand. Overall, attendees can expect valuable sessions on new therapies and disease management, not just in urticaria but across various conditions in allergy and immunology.
